164. Potential utilization of minocycline as a radioprotective agent in the brain

S. Mehrotra; M.J. Pecaut; L. Ortloff; S. Rightnar; C. Perez; G. Harding; D.S. Gridley; Shalini M. Carter

doi:10.1016/j.bbi.2012.07.188

164. Potential utilization of minocycline as a radioprotective agent in the brain

S. Mehrotra, M.J. Pecaut, L. Ortloff, S. Rightnar, C. Perez, G. Harding, D.S. Gridley, Shalini M. Carter

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Brain Behavior and Immunity
Volume	26
DOIs	https://doi.org/10.1016/j.bbi.2012.07.188
State	Published - Sep 1 2012

Disciplines

Internal Medicine
Medicine and Health Sciences
Endocrinology
Immunology and Infectious Disease
Oncology
Biology

Access to Document

10.1016/j.bbi.2012.07.188License: Unspecified

OpenUrl availability

Full text

Cite this

@article{c7272d936e9142aa89443d95156e64ba,

title = "164. Potential utilization of minocycline as a radioprotective agent in the brain",

author = "S. Mehrotra and M.J. Pecaut and L. Ortloff and S. Rightnar and C. Perez and G. Harding and D.S. Gridley and Carter, {Shalini M.}",

note = "Roughly 50% of adult and 100% of pediatric cancer survivors who receive whole-brain irradiation for metastatic disease will develop cognitive dysfunction. Patients who are subjected to cranial radiotherapy for management of primary and metastatic tumors (∼200,000/year) are at the highest risk for neuropsychological deficits.",

year = "2012",

month = sep,

day = "1",

doi = "10.1016/j.bbi.2012.07.188",

language = "American English",

volume = "26",

journal = "Brain Behavior and Immunity",

}

TY - JOUR

T1 - 164. Potential utilization of minocycline as a radioprotective agent in the brain

AU - Mehrotra, S.

AU - Pecaut, M.J.

AU - Ortloff, L.

AU - Rightnar, S.

AU - Perez, C.

AU - Harding, G.

AU - Gridley, D.S.

AU - Carter, Shalini M.

N1 - Roughly 50% of adult and 100% of pediatric cancer survivors who receive whole-brain irradiation for metastatic disease will develop cognitive dysfunction. Patients who are subjected to cranial radiotherapy for management of primary and metastatic tumors (∼200,000/year) are at the highest risk for neuropsychological deficits.

PY - 2012/9/1

Y1 - 2012/9/1

UR - https://www.sciencedirect.com/science/article/pii/S0889159112003716

U2 - 10.1016/j.bbi.2012.07.188

DO - 10.1016/j.bbi.2012.07.188

M3 - Article

VL - 26

JO - Brain Behavior and Immunity

JF - Brain Behavior and Immunity

ER -

164. Potential utilization of minocycline as a radioprotective agent in the brain

Disciplines

Access to Document

OpenUrl availability

Other files and links

Cite this